Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Cases of patients treated in countries with limited resources and discussed by experts of the iCMLf - Case No 2: TFR after 9 years of imatinib treatment without prior achievement of sustained DMR (Michalowski MB et al. Case Reports in Oncological Medicine

Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)—Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.
Michalowski, MB et al. Case Reports in Oncological Medicine, March 2025 – open access publication

 

 

 

 

Management of children and adolescents with chronic myeloid leukemia in chronic-phase: International pediatric CML expert panel recommendations (Millot F et al. Leukemia, March 2025)

Management of children and adolescents with chronic myeloid leukemia in chronic-phase: International pediatric chronic myeloid leukemia expert panel recommendations
Millot F et al. Leukemia, March 2025 (epub ahead of print)

 

 

 

 

Favourable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era (Yoshikawa T et al. Int J Hematol, March 2025)

Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era
Yoshikawa T et al. Int J Hematol, March 2025 (epub ahead of print) – open access publication

 

 

 

 

Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia. Data from a real-world setting (Suttorp M et al. Br J Haematol, March 2025)

Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Data from a real-world setting
Suttorp M et al. Br J Haematol, March 2025 (epub ahead of print) – open access publication

 

 

 

 

Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with CML (Seiser E et al. J Mol Diagn, January 2025)

Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia
Seiser E et al. J Mol Diagn, January 2025 (epub ahead of print)

 

 

 

 

  1. Optimizing diagnostic tools and outcomes evaluation for t(9;22)-positive leukemias in pediatric LMIC patients (Bukhari SI et al. Cancer Invest, January 2025)
  2. Growth retardation and adult height in pediatric patients with chronic-phase CML treated with TKIs (Shima H et al. Leukemia, Dec 2024)
  3. Treatment-free remissions in children with CML: A prospective study from the Tata Memorial Hospital (TMA) Pediatric CML cohort (Roy Moulik N et al. Am J Hematol, Nov. 2024)
  4. Clinical characteristics and outcomes of CML in adolescents and young adults (Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024)